Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
91 participants
OBSERVATIONAL
2021-12-01
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Resection for Multiple Hepatocellular Carcinomas (HCC)
NCT01387061
Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma
NCT02613156
Surgery for Recurrent Intrahepatic Cholangiocarcinoma
NCT04072250
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma
NCT03652896
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
NCT01460745
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treatment of Hepatocellular Carcinoma Patients in RSCM HCC patients are managed by a multidisciplinary team (MDT) consisting of hepatologists, radiologists, pathologists, radiation oncologists, surgeons, and other specialists related to the patient's condition. Confirmed HCC patients are discussed in a weekly MDT team meeting. The meeting assigned patients to treatment options according to the Barcelona Clinic Liver Center (BCLC) staging system, patient preference, and other clinical considerations. Resection is considered for patients at very early (BCLC 0) or early (BCLC A) HCC stages. This includes CP class A patients with a single tumor or less than three small (\<3 cm) tumors. Patients assigned to surgical resection underwent either laparoscopic or open surgery. One to four segments of the liver were removed. Tissue samples were taken for further pathologic examination.
Ethical Clearance The ethics committee of The Faculty of Medicine, University of Indonesia, approved this study by giving an ethical clearance with protocol number 19-11-1313. Informed consent was taken from all patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liver resection
Patients undergoing liver resection due to hepatocellular carcinoma from 2010 to 2021 in RSCM, Jakarta, an academic tertiary-level national referral hospital in Indonesia.
Liver Resection
Resection of a part of the liver afflicted by hepatocellular carcinoma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liver Resection
Resection of a part of the liver afflicted by hepatocellular carcinoma
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with other malignancies
* Patients undergoing other treatment methods for hepatocellular carcinoma.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr Cipto Mangunkusumo General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ridho Ardhi Syaiful
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Cipto Mangunkusumo General Hospital
Jakarta Pusat, DKI Jakarta, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DRCiptoMGH 19-11-1313
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.